MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells - PubMed (original) (raw)

. 2015 Oct 6;22(4):590-605.

doi: 10.1016/j.cmet.2015.08.015. Epub 2015 Sep 10.

Emma Burgos-Ramos 2, Alejandra Tavera 2, Tony Bou Kheir 3, Petra Jagust 3, Matthieu Schoenhals 3, David Barneda 3, Katherine Sellers 4, Ramon Campos-Olivas 5, Osvaldo Graña 6, Catarina R Viera 2, Mariia Yuneva 4, Bruno Sainz Jr 2, Christopher Heeschen 7

Affiliations

Free article

MYC/PGC-1α Balance Determines the Metabolic Phenotype and Plasticity of Pancreatic Cancer Stem Cells

Patricia Sancho et al. Cell Metab. 2015.

Free article

Abstract

The anti-diabetic drug metformin targets pancreatic cancer stem cells (CSCs), but not their differentiated progenies (non-CSCs), which may be related to distinct metabolic phenotypes. Here we conclusively demonstrate that while non-CSCs were highly glycolytic, CSCs were dependent on oxidative metabolism (OXPHOS) with very limited metabolic plasticity. Thus, mitochondrial inhibition, e.g., by metformin, translated into energy crisis and apoptosis. However, resistant CSC clones eventually emerged during treatment with metformin due to their intermediate glycolytic/respiratory phenotype. Mechanistically, suppression of MYC and subsequent increase of PGC-1α were identified as key determinants for the OXPHOS dependency of CSCs, which was abolished in resistant CSC clones. Intriguingly, no resistance was observed for the mitochondrial ROS inducer menadione and resistance could also be prevented/reversed for metformin by genetic/pharmacological inhibition of MYC. Thus, the specific metabolic features of pancreatic CSCs are amendable to therapeutic intervention and could provide the basis for developing more effective therapies to combat this lethal cancer.

Copyright © 2015 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Comment in

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources